

Supplemental Tables for:  
Combined effect of sarcopenia and systemic inflammation on survival in advanced stage cancer patients treated with immunotherapy  
Mehmet Bilen et al.

**Supplemental Table S1:** UVA and MVA<sup>a</sup> of NLR-based risk groups and survival

	UVA				MVA			
	OS		PFS		OS		PFS	
	HR (CI)	p-value	HR (CI)	p-value	HR (CI)	p-value	HR (CI)	p-value
<b>Group 1: Low Risk</b> NLR < 4.6 and Non-Sarcopenic (n=25)	--	--	--	--	--	--	--	--
<b>Group 2: Intermediate Risk</b> NLR < 4.6 and Sarcopenic (n=28)	1.69 (0.81- 3.50)	0.161	1.53 (0.86- 2.72)	0.151	4.71 (1.90- 11.67)	<b>&lt;0.001<sup>b</sup></b>	1.96 (1.05- 3.67)	<b>0.034<sup>b</sup></b>
<b>Group 3: High Risk</b> NLR ≥ 4.6 and Non-Sarcopenic (n=10)	2.84 (1.18- 6.82)	<b>0.020<sup>b</sup></b>	3.33 (1.53- 7.27)	<b>0.003<sup>b</sup></b>	4.33 (1.60- 11.73)	<b>0.004<sup>b</sup></b>	4.16 (1.81- 9.60)	<b>&lt;0.001<sup>b</sup></b>
<b>Group 4: Very High Risk</b> NLR ≥ 4.6 and Sarcopenic (n=16)	4.19 (1.91- 9.20)	<b>&lt;0.001<sup>b</sup></b>	4.60 (2.31- 9.16)	<b>&lt;0.001<sup>b</sup></b>	6.53 (2.23- 19.14)	<b>&lt;0.001<sup>b</sup></b>	4.43 (1.86- 10.52)	<b>&lt;0.001<sup>b</sup></b>

<sup>a</sup>The multivariable model was built by controlling for gender, checkpoint indication, number of previous treatment lines, Royal Marsden Hospital (RMH) risk group, age, ECOG PS, race, number of metastatic sites, and histology

<sup>b</sup>Statistical significance at alpha < 0.05

**Supplemental Table S2:** UVA and MVA<sup>a</sup> of MLR-based risk groups and survival

	UVA				MVA			
	OS		PFS		OS		PFS	
	HR (CI)	p-value	HR (CI)	p-value	HR (CI)	p-value	HR (CI)	p-value
<b>Group 1: Low Risk</b> MLR < 0.38 and Non-Sarcopenic (n=16)	--	--	--	--	--	--	--	--
<b>Group 2: Intermediate Risk</b> MLR < 0.38 and Sarcopenic (n=14)	1.46 (0.52- 4.09)	0.468	1.60 (0.74- 3.46)	0.235	3.51 (0.94- 13.06)	0.061	1.65 (0.71- 3.81)	0.243
<b>Group 3: High Risk</b> MLR ≥ 0.38 and Non-Sarcopenic (n=19)	3.03 (1.26- 7.32)	<b>0.014<sup>b</sup></b>	2.91 (1.38- 6.11)	<b>0.005<sup>b</sup></b>	3.45 (1.17- 10.22)	<b>0.025<sup>b</sup></b>	2.16 (0.99- 4.71)	0.054
<b>Group 4: Very High Risk</b> MLR ≥ 0.38 and Sarcopenic (n=30)	4.63 (1.97- 10.87)	<b>&lt;0.001<sup>b</sup></b>	3.50 (1.78- 6.88)	<b>&lt;0.001<sup>b</sup></b>	10.70 (3.45- 33.14)	<b>&lt;0.001<sup>b</sup></b>	2.91 (1.41- 6.00)	<b>0.004<sup>b</sup></b>

<sup>a</sup>The multivariable model was built by controlling for gender, checkpoint indication, number of previous treatment lines, Royal Marsden Hospital (RMH) risk group, age, ECOG PS, race, number of metastatic sites, and histology

<sup>b</sup>Statistical significance at alpha < 0.05